AbbVie's Got A Competitive Edge With Elagolix For Women With Uterine Fibroids

 
• By Jessica Merrill

AbbVie announced positive data from the first of two pivotal Phase III studies testing the GnRH receptor antagonist, but Allergan and Myovant are among the companies also looking to bring new drugs to market.

airport runway under the sun as background

More from Immunological

More from Therapy Areas